Evidence map›Paper›PMID 34110300›Full record

ArticleJournal of medical Internet research2021

Acceptability of the Medication Event Reminder Monitor for Promoting Adherence to Multidrug-Resistant Tuberculosis Therapy in Two Indian Cities: Qualitative Study of Patients and Health Care Providers.

Beena E Thomas, J Vignesh Kumar, Murugesan Periyasamy, Amit Subhash Khandewale, J Hephzibah Mercy, E Michael Raj, S Kokila, Apurva Shashikant Walgude, Gunjan Rahul Gaurkhede, Jagannath Dattatraya Kumbhar and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of medical Internet research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Beena E Thomas *Department of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0003-1973-2212
J Vignesh KumarDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0003-0238-598X
Murugesan PeriyasamyDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0001-8352-7323
Amit Subhash KhandewaleDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0003-2713-2524
J Hephzibah MercyDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-2213-0602
E Michael RajDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0001-6509-1570
S KokilaDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0003-1814-1998
Apurva Shashikant WalgudeDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0001-7975-4099
Gunjan Rahul GaurkhedeDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-1655-4548
Jagannath Dattatraya KumbharDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-9519-456X
Senthanro OvungDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0003-2893-4932
Mariyamma PaulDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-0324-4858
B Sathyan RajkumarDepartment of Social and Behavioural Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-1095-0363
Ramnath Subbaraman *Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, United States.ORCID 0000-0002-2063-943X
National Institute of Research in Tuberculosis · INTufts University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Harvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5M
Doris Duke Charitable Foundation 2018095NCATS NIH HHS KL2 TR001100NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

backgroundPatients with multidrug-resistant tuberculosis (MDR-TB) face challenges adhering to medications, given that treatment is prolonged and has a high rate of adverse effects. The Medication Event Reminder Monitor (MERM) is a digital pillbox that provides pill-taking reminders and facilitates the remote monitoring of medication adherence.

objectiveThis study aims to assess the MERM's acceptability to patients and health care providers (HCPs) during pilot implementation in India's public sector MDR-TB program.

methodsFrom October 2017 to September 2018, we conducted qualitative interviews with patients who were undergoing MDR-TB therapy and were being monitored with the MERM and HCPs in the government program in Chennai and Mumbai. Interview transcripts were independently coded by 2 researchers and analyzed to identify the emergent themes. We organized findings by using the Unified Theory of Acceptance and Use of Technology (UTAUT), which outlines 4 constructs that predict technology acceptance-performance expectancy, effort expectancy, social influence, and facilitating conditions.

resultsWe interviewed 65 patients with MDR-TB and 10 HCPs. In patient interviews, greater acceptance of the MERM was related to perceptions that the audible and visual reminders improved medication adherence and that remote monitoring reduced the frequency of clinic visits (performance expectancy), that the device's organization and labeling of medications made it easier to take them correctly (effort expectancy), that the device facilitated positive family involvement in the patient's care (social influences), and that remote monitoring made patients feel more cared for by the health system (facilitating conditions). Lower patient acceptance was related to problems with the durability of the MERM's cardboard construction and difficulties with portability and storage because of its large size (effort expectancy), concerns regarding stigma and the disclosure of patients' MDR-TB diagnoses (social influences), and the incorrect understanding of the MERM because of suboptimal counseling (facilitating conditions). In their interviews, HCPs reported that MERM implementation resulted in fewer in-person interactions with patients and thus allowed HCPs to dedicate more time to other tasks, which improved job satisfaction.

conclusionsSeveral features of the MERM support its acceptability among patients with MDR-TB and HCPs, and some barriers to patient use could be addressed by improving the design of the device. However, some barriers, such as disease-related stigma, are more difficult to modify and may limit use of the MERM among some patients with MDR-TB. Further research is needed to assess the accuracy of MERM for measuring adherence, its effectiveness for improving treatment outcomes, and patients' sustained use of the device in larger scale implementation.

Indexed as

Antitubercular AgentsTuberculosis, Multidrug-ResistantCitiesHealth PersonnelHumansIndiaMedication AdherenceAntitubercular Agentsdigital adherence technologiesdrug-resistantIndiamedication adherencemHealthtuberculosis

Identifiers

PMID34110300
PMCPMC8262665
OpenAlexW3171941571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.